http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017531632-A
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-0105 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47 |
filingDate | 2015-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2017-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-2017531632-A |
titleOfInvention | Methods for treating mucopolysaccharidosis type IIIB (MPSIIIB) |
abstract | A method of treating the central nervous system (CNS) of a human patient having mucopolysaccharidosis (MPS) type IIIB and having an intact blood-brain barrier, comprising intravenous administration of recombinant NaGlu. A method for treating the central nervous system (CNS) of a human patient having mucopolysaccharidosis (MPS) type IIIB undergoing long-term enzyme replacement therapy with recombinant human N-acetyl-α-D-glucosaminidase (rhNaGlu), The method includes the step of intravenously administering to the patient a therapeutically effective amount of rhNaGlu to prevent re-accumulation of heparan sulfate levels in cerebrospinal fluid (CSF), wherein the patient: CSF / serum albumin index; CSF / serum IgG index; CSF IgG index; and / or an intact blood brain barrier (BBB) as determined by dynamic contrast enhanced magnetic resonance imaging (DCEMRI), wherein said intravenous The method wherein administration prevents re-accumulation of heparan sulfate levels in the CSF. |
priorityDate | 2014-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 428.